SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing busi ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Z ...

Halozyme Therapeutics (HALO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sco ...

| --- | --- | --- | |----------------------------------------------------------|-------|-------| | | | | | Halozyme Therapeutics, Inc. | | | | Fourth Quarter and FY 2023 Financial & Operating Results | | | | | | | | NASDAQ: HALO | | | | February 20, 2024 | | | | | | | In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________________________ Delaware 88-0488 ...

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non- GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non- GAAP Diluted EPS of $0.82 1 SAN DIEGO, February 20, 2024 -- Halozyme Therapeutics, ...

Financial Data and Key Metrics Changes - Revenue for Q3 2023 was $216 million, an increase from $209 million in the prior year period, driven by higher enhanced product sales and royalty growth [27][120] - Royalty revenue for Q3 2023 increased 15% year-over-year to approximately $114 million, continuing to be a key driver of revenue growth [16][56] - EBITDA guidance was raised to $430 million to $445 million, up from $420 million to $440 million, representing growth of 37% to 41% over 2022 [12][29] - Non-GAAP diluted earnings per share guidance was increased to $2.70 to $2.80, reflecting an annual growth of 22% to 27% [30][57] Business Line Data and Key Metrics Changes - The ENHANZE technology and high volume auto-injector are expected to drive strong and durable long-term revenue growth for the company [8] - XYOSTED demand in Q3 2023 continued to grow, contributing to a 32% increase in year-to-date demand compared to 2022, with projected sales of approximately $100 million in 2022 [24] - The approval of VYVGART Hytrulo is expected to expand the commercial opportunity in a condition with significant unmet need, with growth of 22% quarter-over-quarter to $329 million in Q3 2023 [126] Market Data and Key Metrics Changes - Roche reported Q3 2023 DARZALEX sales of approximately $2.5 billion, an increase of about 21% year-over-year, with projections for annual sales to reach $17 billion by 2028 [125] - Roche's IV Tecentriq revenues for year-to-date 2023 were CHF2.8 billion, an increase of 11% year-over-year [48] - Analysts predict that efgartigimod will be a multi-billion dollar annual revenue brand by 2028 [126] Company Strategy and Development Direction - The company plans to continue investing at similar levels to grow the business in 2024, with a strong balance sheet and projected EBITDA growth [41] - The company is focused on seeking growth opportunities through M&A while maintaining a disciplined capital allocation strategy [7][55] - The Wave 3 products are projected to achieve approximately $35 billion in sales by 2028, significantly higher than the $20 billion projected for Wave 2 products [50] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the Wave 3 products being largely derisked, with four launches expected between 2023 and 2025 [3] - The company is optimistic about the potential for OCREVUS subcutaneous to significantly increase market access and patient convenience [39] - Management highlighted the strong performance and momentum in the quarter, indicating confidence in meeting updated revenue guidance [120] Other Important Information - The company announced an accelerated share repurchase of $250 million, bringing total buybacks since 2019 to $1.3 billion [26][121] - The company is focusing on expanding its ENHANZE partnerships and has made strong progress in advancing its high volume auto-injector technology [43][134] Q&A Session Summary Question: Can you comment on the timeline for the Auto-Injector technology development? - The timeline for developing an Auto-Injector from concept to product is estimated to be around two years, depending on the product type and necessary studies [32][62] Question: What are the drivers of XYOSTED growth this quarter? - The growth is driven by converting patients from intramuscular testosterone therapy to XYOSTED and ensuring prior authorizations are filled [69][79] Question: What is the expected conversion rate for OCREVUS from IV to subcutaneous? - The conversion rate is difficult to predict, but there is optimism for significant growth based on the value proposition and patient convenience [66][101] Question: Why is the deal with Acumen non-exclusive? - The deal is non-exclusive because there is already another partner with non-exclusive access to the amyloid beta target, allowing for multiple partnerships [76][115] Question: What are the economic terms associated with the Auto-Injector contracts? - The economic terms will likely include development down payments and product sales, similar to current ENHANZE contracts [108][109]

Dollar amounts, as presented, are rounded. Consequently, totals may not add up. (1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the Antares acquisition. (2) Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition. (3) Amounts relate to fair value gain on contingent liability, inventory write-off and impairment of TLANDO® product rights intangible assets due to the termination of the T ...